Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR‐Preserved trial.

This is important for not only the mortality and morbidity outcomes but for health status also, as HF patients suffer from significantly impaired health-related quality of life (HRQoL). Patients with chronic heart failure (HF) are at a high risk for adverse outcomes and once hospitalized, the risk for readmission is ~20-25 at 1 month and ~50% at 6 months, with a 1-year post-discharge mortality rate ranging between 20% and 30%.1 Given the high risk of morbidity and mortality in both the chronic and the worsening HF settings, it is important to have therapies that not only improve overall outcomes, but that the onset of benefit is early post-initiation. Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. [Extracted from the article]